Filing Flows › Aytu Biopharma (AYTU) › Q4 FY26
Aytu Biopharma (AYTU) Q4 FY26 earnings results (fourth quarter fiscal 2026)
10-K filed Sep 22, 2026
Aytu Biopharma (AYTU) reported revenue of $16.1M for the fourth quarter fiscal 2026 (Q4 FY26), +6% from a year earlier and +30% from the quarter before. Operating margin was -4.8%, net loss $15K (0.1% of revenue).
Aytu Biopharma, Q4 FY26: revenue $16.1M (+6% year over year), operating margin -4.8%, net loss $15K, operating cash flow $4.4M. The chart follows the revenue to costs, profit and cash.
| Q4 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $16.1M | +30% | +6% |
| Operating profit | −$777K | — | — |
| Net earnings | −$15K | — | — |
| Operating cash flow | $4.4M | — | +57% |
| Free cash flow | $4.4M | — | +58% |
What changed
Revenue was $16.1M in Q4 FY26, up 6% year over year and up 30% from the previous quarter.
Gross margin was 64.6%, down 3.1 points from Q4 FY25. Operating costs exceeded revenue by $777K, an operating margin of -4.8%. Operating expenses fell 37% while revenue rose 6%. The fastest-growing cost line was Sales & marketing (+28%). The quarter ended with a net loss of $15K, narrower than the previous quarter's $5.6M loss. Non-operating items added $773K, -19325% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $4.4M (up 57% year over year). Non-cash charges added back $1.1M of depreciation and amortization and $146K of share-based compensation. Working capital and other items added $3.2M. Capital expenditures of $12K left free cash flow of $4.4M.
Questions
What was Aytu Biopharma's revenue in the fourth quarter fiscal 2026?
Aytu Biopharma (AYTU) reported revenue of $16.1M for the fourth quarter fiscal 2026 (Q4 FY26), +6% from a year earlier and +30% from the quarter before.
Was Aytu Biopharma profitable in the fourth quarter fiscal 2026?
Operating loss was $777K (-4.8% of revenue) and net loss $15K.
Source: Aytu Biopharma 10-K on SEC EDGAR.